

<sup>a</sup> Medical Assistance Institute, Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brazil

<sup>b</sup> Department of Dermatology, Complexo Hospitalar Padre Bento de Guarulhos, São Paulo, SP, Brazil

\* Corresponding author.

E-mail: [lpiresventura@gmail.com](mailto:lpiresventura@gmail.com) (L.P. Ventura).

Received 7 August 2023; accepted 29 September 2023  
Available online 20 May 2024

<https://doi.org/10.1016/j.abd.2023.09.008>

0365-0596/ © 2024 Sociedade Brasileira de Dermatologia.

Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## Dermoscopic changes of tattoos over melanocytic nevi<sup>☆</sup>



Dear Editor,

The prevalence of tattoos in the population has increased and dermatologists must be familiar with its complications. The survey carried out by Kluger et al. showed a prevalence of tattooed individuals in Brazil of 22.3%; the most prevalent age group being 25–34 years old (30.3%).<sup>1</sup> Bicca et al. analyzed the prevalence of tattoos in recruits in Pelotas, Rio Grande do Sul, and the result was 10.82% of 1,968 recruits.<sup>2</sup>

Nevi traumatized by tattooing may undergo changes that increase the suspicion of malignancy, such as cytological atypia, pagetoid spreading and dermal mitosis; therefore, nevi, pigmented lesions, or melanoma scars should not be tattooed. Tattooing pigment in nevi can either delay the diagnosis of malignant transformation or simulate findings of malignancy, resulting in unnecessary surgery. It is recommended to avoid tattooing areas of the body with an abundance of nevi, keeping a margin of 0.5 to 1 cm from these lesions. Patients with atypical nevi syndrome or a personal or family history of melanoma should consult a dermatologist prior to tattooing.<sup>3–6</sup>


A cross-sectional study was carried out, using convenience sampling between December 2021 and July 2022, at the Dermatology Outpatient Clinic of Hospital de Clínicas de Porto Alegre, in Porto Alegre, Rio Grande do Sul, Brazil. The inclusion criterion was having a tattoo. Exclusion criteria were being under 18 years of age or having some physical or psychiatric disability that made it impossible to understand the study and/or sign the Informed Consent Form. The tattoos were inspected and when they were over a nevus, the lesion was photographed and stored using a FotoFinder equipment. The dermoscopic characteristics were analyzed jointly by the researchers. This study was approved by the Ethics Committee under protocol number 52210121.2.0000.5327.

A total of 112 individuals participated in the research, who had 485 tattoos. Of these, 82 (16.9%) were located over melanocytic nevi, with a total of 194 nevi being tattooed. The study by Kluger retrospectively analyzed complications in 31 patients with tattoos and observed 10% tattooed nevi.<sup>7</sup> This value is lower than that was found in the present study, which can be justified because this was a cross-sectional

study in which all tattoos were inspected actively looking for nevi.


The following dermoscopic changes were observed in tattooed nevi: dots, globules, erythema, tattoo obliteration, amorphous blurring, blue veil, densification of the nevus pigment, partial obliteration of the nevus pigment, total obliteration of the nevus pigment, pseudonetwork and perifollicular pigment. Figs. 1–4 demonstrate some aspects observed in the study.

Blurring was seen as amorphous dark areas in the nevus, and was the most observed change, present in 108 nevi (55.7%). Tattooing pigment present in small dots was present in 93 nevi (47.9%); while larger round clusters with the appearance of globules were present in 70 nevi (36.1%). Tattooing pigment present in small quantities in the nevus



**Fig. 1** (A) Tattoo pigment in an amorphous blurring pattern with an area of densification of the melanocytic network on the left edge and an area of blue veil on the lower edge of the nevus. (B) Tattoo pigment in a pattern of dots and globules.

<sup>☆</sup> Study conducted at the Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.



**Fig. 2** (A) Tattooing pigment with a lacy presentation characterized as a pseudonetwork. (B) Red tattooing pigment simulating erythema.


caused densification of the melanocytic network in 26 nevi (13.4%). An important observation is the blue veil – a pattern attributed to malignant melanocytic lesions – observed in 16.5% of the nevi in this study (Fig. 1).

The pseudonetwork pattern was seen as a lacy tattoo pigmentation in 30 nevi (15.5%). Erythema was observed in eight nevi (4.1%), and was present only in red pigment tattoos (Fig. 2).

Heavier tattooing caused obliteration of the nevus, attributed in this study as partial if it was still possible to observe the melanocytic pattern interspersed with the tattooing pigment, or total when it was only possible to observe the tattooing pigment (Fig. 3). These patterns were present in 44.3% and 21.1% of nevi respectively, and can hide asymmetries and other suspicious findings in nevi, which is a matter of concern, as together they were present in almost two-thirds of the nevi.

Perifollicular pigmentation was observed in only two nevi (1.0%). An interesting presentation, observed in 4.1% of nevi, was tattoo obliteration, in which the nevus stood out and there was an abrupt interruption of the tattooing pigmentation (Fig. 4). The authors believe this pattern may be associated with the appearance or growth of the nevus after the tattoo, and that histopathological evaluation could be informative.

On most occasions, the examiner can differentiate between changes caused by tattooing and changes due to the



**Fig. 3** (A) Tattooing pigment causing partial obliteration of the nevus and (B) total obliteration of the nevus, in which the melanocytic network cannot be clearly observed in the tattooed area.

nevus. However, tattooing pigment can cause obliteration of the nevus, impairing the observation of the melanocytic network and consequently the screening for melanoma. To the best of the authors knowledge, this is the first study analyzing the dermoscopic patterns of nevi that have undergone tattooing.

### Financial support


None declared.

### Authors' contributions

Felipe Miguel Farion Watanabe: Design and planning of the study; collection, analysis and interpretation of data; drafting and editing of the manuscript; critical review of the literature.

Lia Dias Pinheiro Dantas: Design and planning of the study; effective participation in research orientation; approval of the final version of the manuscript.

Renan Rangel Bonamigo: Design and planning of the study; analysis and interpretation of data; effective participation in research orientation; approval of the final version of the manuscript.



**Fig. 4** (A) Perifollicular concentration of tattooing pigment. (B) Nevus causing obliteration of the tattoo; melanin pigmentation extends over the tattoo. Abrupt interruption of the tattooing pigment is observed indicating the possibility of the nevus having appeared after tattooing.

### Conflicts of interest

None declared.

### References

1. Kluger N, Seit  S, Taieb C. The prevalence of tattooing and motivations in five major countries over the world. *J Eur Acad Dermatol Venereol.* 2019;33:e484-6.
2. Bicca JF, Duquia RP, Breunig JA, Souza PRM, Almeida HL Jr. Tattoos on 18-year-old male adolescents – characteristics and associated factors. *An Bras Dermatol.* 2013;88:925-8.
3. Juhas E, English JC 3rd. Tattoo-associated complications. *J Pediatr Adolesc Gynecol.* 2013;26:125-9.
4. Kluger N. Contraindications for tattooing. *Curr Probl Dermatol.* 2015;48:76-87.
5. Kluger N, De Cuyper C. A practical guide about tattooing in patients with chronic skin disorders and other medical conditions. *Am J Clin Dermatol.* 2018;19:167-80.
6. De Cuyper C. How to advise a patient who wants a tattoo? *Presse Med.* 2020;49:104048.
7. Kluger N. Cutaneous complications related to tattoos: 31 cases from Finland. *Dermatology.* 2017;233:100-9.

Felipe Miguel Farion Watanabe <sup>a,\*</sup>,  
Lia Dias Pinheiro Dantas <sup>b</sup>, Renan Rangel Bonamigo <sup>a,c</sup>

<sup>a</sup> Department of Dermatology, Hospital de Cl nicas de Porto Alegre, Porto Alegre, RS, Brazil

<sup>b</sup> Postgraduate program in Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

<sup>c</sup> Department of Internal Medicine, Faculty of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

\* Corresponding author.

E-mail: [Felipem.farion@gmail.com](mailto:Felipem.farion@gmail.com) (F.M. Watanabe).

Received 18 May 2023; accepted 7 August 2023

Available online 31 May 2024

<https://doi.org/10.1016/j.abd.2023.08.015>

0365-0596/  2024 Published by Elsevier Espa a, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

### Is arteriovenous fistula a risk factor for squamous cell carcinoma? Evaluation at a University Hospital<sup> </sup>



Dear Editor,

Squamous cell carcinoma (SCC) is the most common neoplasm in transplant (TX) patients, when it is more aggressive and presents a worse prognosis.<sup>1,2</sup> In kidney transplant recipients the occurrence of SCCs is over or close to arteriovenous fistulas (AVF), whether they are active or not. Two mechanisms are proposed: impaired immune response due to overload of the lymphatic system of the affected extremity

and, facilitation of HPV-related tumors secondary to surgical trauma due to fistula formation, repetitive punctures, and excision of multiple tumors.<sup>3</sup> Moreover, 3.7%–5% of dialysis patients develop limb ischemia, leading to oxidative stress that can potentiate carcinogenic factors for the development of SCC.<sup>3</sup> After kidney transplantation, many patients remain with an AVF and start using immunosuppressants. These medications add a risk of up to 100  for the development of SCC.<sup>4-6</sup> There is also a greater susceptibility to the HPV virus, with DNA from the virus being found in 80% of SCCs in immunosuppressed patients.<sup>6</sup>

Data from the literature show a high incidence of skin tumors in kidney transplant recipients, but there are no studies that analyze whether the fistula influences tumor development. Therefore, this project aims to report three cases of SCCs appearing close to fistulas, explaining their challenges and analyzing the occurrence of these tumors, whether this association is true or not.

<sup> </sup> Study conducted at the Universidade Estadual de Campinas, Campinas, SP, Brazil.